The order focuses on improving coordination between the FDA and the Department of Veterans Affairs so research data can be reviewed more efficiently. It also calls for faster rescheduling of approved psychedelic medicines, which could make medical access and research easier in the future.
Trump pointed to studies involving treatments such as ibogaine, including research on veterans that reportedly showed major reductions in depression and anxiety symptoms. The initiative also highlights state and federal investment in psychedelic research and possible use under “Right to Try” laws for patients with severe conditions.
The announcement fits into a broader push to reshape federal systems in healthcare and election administration. Supporters see these moves as efforts to reduce delays and modernize policy, while critics worry about oversight, safety, and the risks of expanding federal power too quickly.
